Ligand Pharmaceuticals, Inc. (LGND) Misses Q3 EPS by 5c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $318.13 +1.30%
Revenue Growth %: +32.4%
Financial Fact:
Cost of sales: 999K
Today's EPS Names:
DTGI, CRMT, STZ, More
Revenue Growth %: +32.4%
Financial Fact:
Cost of sales: 999K
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q3 EPS of ($0.01), $0.05 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $6.4 million versus the consensus estimate of $8.4 million.
Separately, the company announced it is restating LFY11, Q112, Q212 financials.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Separately, the company announced it is restating LFY11, Q112, Q212 financials.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer turns cautious on major U.S. banks, favors alternative asset managers
- CPKC to report second-quarter 2026 earnings results on July 29
- Lemonade cuts quota share cession to 18% in reinsurance renewal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
